Oclaiz

Business news, market intelligence, and global industry analysis.

The Latest

Dhurandhar: The Revenge crosses Rs 805 crore India gross, Rs 1,067 crore worldwide by day 8

Representative image of explosions over Tehran after unprecedented Israeli strikes, as stalled United States peace talks and another delayed Hormuz deadline deepen fears of a wider Middle East war.

Tehran hit by unprecedented Israeli strikes as U.S. peace talks stall and Hormuz deadline pushed again

Representative image of a fuel station in India after the excise duty cut on petrol and diesel, as the Hormuz crisis pushes up India’s energy import bill and raises pressure on fuel pricing policy.

Petrol duty slashed to Rs 3, diesel to zero as Hormuz crisis hits India’s energy bill

Representative image of grounded passenger aircraft at an Indian airport, illustrating the story on how soaring fuel costs, Gulf airspace disruption, and Directorate General of Civil Aviation schedule cuts are worsening the summer 2026 crisis for Indian airlines.

Fuel up 85%, Gulf closed: India airlines face worst summer since Covid as DGCA trims 2026 schedule

Camurus resubmits Oclaiz for FDA review as subcutaneous acromegaly therapy eyes June 2026 decision

Camurus's Oclaiz is back in FDA review for acromegaly. Find out what the June 2026 decision could mean for U.S. access and endocrine market disruption.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

January 12, 2026